Last Updated on October 17, 2024 by The Health Master
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, the company said in a statement.
It also said that the approved ANDA is therapeutically equivalent to the reference listed drug (RLD) product, Anafranil Capsules, 25 mg, 50 mg and 75 mg, of SpecGX LLC.
Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD).
Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, have an estimated market size of $32 million for twelve months ending June 2021, according to IQVIA, the statement added.
“Alembic has a cumulative total of 149 ANDA approvals (131 final approvals and 18 tentative approvals) from FDA,” it further mentioned.
Zydus Cadila gets final nod from USFDA for Fulvestrant injection
USFDA inspection ends with ‘Zero’ observations: Alkem
Granules Pharma clears USFDA audit
Zydus Cadila gets USFDA nod for Ibrutinib tablets
Lupin gets USFDA nod for generic Antifungal drug
Unichem gets tentative USFDA nod for drug to treat Diabetes
7 Tips Every Men Should Follow In Healthy Skincare Regime
Only 0.20% of drug samples declared Adulterated in FY 2020-21
Govt to amend New Drugs and Clinical Trials Rules 2019
CDSCO approves 12 laboratories for BA/BE studies
FAQs on Medical Devices Rules, 2017
FAQs on New Drug, Banned drugs etc.
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
